ARZOXIFENE HYDROCHLORIDE

Possibly Marketed Outside US

Details

Stereochemistry	ACHIRAL
Molecular Formula	C28H29NO4S.ClH
Molecular Weight	512.06
Optical Activity	NONE
Defined Stereocenters	0 / 0
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

Cl.COC1=CC=C(C=C1)C2=C(OC3=CC=C(OCCN4CCCCC4)C=C3)C5=CC=C(O)C=C5S2

InChI

InChIKey=NHSNLUIMAQQXGR-UHFFFAOYSA-N

InChI=1S/C28H29NO4S.ClH/c1-31-22-8-5-20(6-9-22)28-27(25-14-7-21(30)19-26(25)34-28)33-24-12-10-23(11-13-24)32-18-17-29-15-3-2-4-16-29;/h5-14,19,30H,2-4,15-18H2,1H3;1H

HIDE SMILES / InChI

Description
Sources: https://www.ncbi.nlm.nih.gov/pubmed/9765314 | https://www.ncbi.nlm.nih.gov/pubmed/16503767 | https://www.ncbi.nlm.nih.gov/pubmed/12964068 | https://adisinsight.springer.com/drugs/800010379

Arzoxifene (LY353381) is a synthetic, nonsteroidal ligand termed selective estrogen receptor modulator. Arzoxifene has antiestrogenic effects on the breast and endometrium, but pro-estrogenic effects on bone and lipids. Arzoxifene has been studied in the treatment of various hormone-responsive neoplasms. Its development has been discontinued.

Originator

Approval Year

PubMed

Title	Date	PubMed
Selective estrogen receptor modulators for the chemoprevention of prostate cancer.	2001 Apr	11295598
Analysis of cross-resistance of the selective estrogen receptor modulators arzoxifene (LY353381) and LY117018 in tamoxifen-stimulated breast cancer xenografts.	2001 Aug	11489833
Prevention and treatment of experimental breast cancer with the combination of a new selective estrogen receptor modulator, arzoxifene, and a new rexinoid, LG 100268.	2002 Oct	12374698
A phase II trial of arzoxifene, a selective estrogen response modulator, in patients with recurrent or advanced endometrial cancer.	2003 Jul	12821343
The use of selective estrogen receptor modulators and selective estrogen receptor down-regulators in breast cancer.	2004 Mar	14687597
The selective estrogen receptor modulator arzoxifene and the rexinoid LG100268 cooperate to promote transforming growth factor beta-dependent apoptosis in breast cancer.	2004 May 15	15150113
Endocrine treatment options for advanced breast cancer--the role of fulvestrant.	2005 Feb	15691633
Effect of the selective estrogen receptor modulator arzoxifene on repopulation of hormone-responsive breast cancer xenografts between courses of chemotherapy.	2005 Nov 15	16299252
Chemical modification modulates estrogenic activity, oxidative reactivity, and metabolic stability in 4'F-DMA, a new benzothiophene selective estrogen receptor modulator.	2006 Jun	16780356
Phase III double-blind trial of arzoxifene compared with tamoxifen for locally advanced or metastatic breast cancer.	2007 Nov 1	17971595
Structure-activity relationships for a family of benzothiophene selective estrogen receptor modulators including raloxifene and arzoxifene.	2007 Oct	17654759
Lasofoxifene for the prevention and treatment of postmenopausal osteoporosis.	2009	19898646
Current and emerging pharmacologic therapies for the management of postmenopausal osteoporosis.	2009 Oct	19857095
The influence of P-glycoprotein expression and its inhibitors on the distribution of doxorubicin in breast tumors.	2009 Oct 6	19807929

Name

Type

Language

ARZOXIFENE HYDROCHLORIDE

Official Name

English

ARZOXIFENE HCL

Common Name

English

ARZOXIFENE HYDROCHLORIDE [MART.]

Common Name

English

LY353381.HCL

Code

English

2-(P-METHOXYPHENYL)-3-(P-(2-PIPERIDINOETHOXY)PHENOXY)BENZO(B)THIOPHENE-6-OL HYDROCHLORIDE

Common Name

English

LY-353381.HCL

Code

English

ARZOXIFENE HYDROCHLORIDE [MI]

Common Name

English

Arzoxifene hydrochloride [WHO-DD]

Common Name

English

ARZOXIFENE HYDROCHLORIDE [USAN]

Common Name

English

SERM 3

Code

English

2-(4-METHOXYPHENYL)-3-(4-(2-(1-PIPERIDINYL)ETHOXY)PHENOXY)BENZO(B)THIOPHENE-6-OL HYDROCHLORIDE

Systematic Name

English

SERM-3

Code

English

Classification Tree Code System Code

NCI_THESAURUS

C1821